NDUFS6 (NADH:Ubiquinone Oxidoreductase Core Subunit S6), also known as TYKY, is a critical iron-sulfur subunit of mitochondrial complex I (NADH:ubiquinone oxidoreductase), the largest enzyme of the mitochondrial electron transport chain. Complex I is essential for oxidative phosphorylation, catalyzing the transfer of electrons from NADH to ubiquinone while pumping protons across the inner mitochondrial membrane to generate the electrochemical gradient used for ATP synthesis. NDUFS6 contains iron-sulfur clusters that are essential for electron transfer, and mutations in this gene cause severe mitochondrial diseases including Leigh syndrome, mitochondrial complex I deficiency, and contribute to more common neurodegenerative conditions such as Parkinson's disease.
| Property |
Value |
| Gene Symbol |
NDUFS6 |
| Full Name |
NADH:Ubiquinone Oxidoreductase Core Subunit S6 |
| Alternative Name |
TYKY |
| Chromosomal Location |
5p14.3 |
| NCBI Gene ID |
4729 |
| OMIM |
602152 |
| Ensembl ID |
ENSG00000145494 |
| UniProt |
O75306 |
| Protein Family |
Complex I subunit family (NADH dehydrogenase) |
| Length |
124 amino acids |
| Molecular Weight |
~13 kDa |
Mitochondrial complex I (NADH:ubiquinone oxidoreductase) is the largest respiratory chain complex, comprising 44 subunits organized into:
- Hydrophobic arm: Embedded in the inner mitochondrial membrane
- Peripheral arm: Extends into the mitochondrial matrix
- Core subunits: 14 essential "economical" subunits conserved from bacteria to humans
- Supernumerary subunits: 30 additional subunits in mammals
NDUFS6 is one of the core subunits, specifically located in the iron-sulfur (Fe-S) fragment of the peripheral arm.
NDUFS6 contains essential iron-sulfur (Fe-S) clusters for electron transfer:
- 2Fe-2S cluster: Primary electron acceptor from NADH
- 4Fe-4S cluster: Electron transfer to ubiquinone
These clusters require proper iron metabolism and sulfur assembly machinery for maturation. Mutations in NDUFS6 can disrupt cluster assembly or stability, compromising complex I function.
Complex I catalyzes:
- NADH oxidation: NADH → NAD+ + 2e- + H+
- Electron transfer: Through Fe-S clusters to ubiquinone
- Proton pumping: 4 protons translocated per NADH oxidized
- Ubiquinol formation: Coenzyme Q10 reduced to CoQH2
This creates the proton gradient that drives ATP synthase (complex V) to produce ATP.
Recessive mutations in NDUFS6 cause classic Leigh syndrome (subacute necrotizing encephalomyelopathy):
Clinical Features:
- Progressive neurodegeneration affecting brainstem, basal ganglia, and thalamus
- Onset in infancy or early childhood (typically 3-18 months)
- Developmental regression, loss of milestones
- Ataxia, dystonia, hypotonia
- Respiratory failure, seizures
- Optical atrophy, hearing loss
Diagnostic Findings:
- Elevated lactate in blood and CSF
- MRI: symmetric T2 hyperintensities in putamen, brainstem
- Severe complex I deficiency (<20% residual activity)
- Poor prognosis, often fatal within 2 years
Molecular Mechanism:
- NDUFS6 mutations reduce complex I assembly/stability
- Impaired NADH oxidation leads to energy failure
- Accumulated NADH drives anaerobic metabolism
- Lactate acidosis and cell death
NDUFS6 mutations cause isolated complex I deficiency:
- Heterogeneous presentation: From severe encephalopathy to mild myopathy
- Tissue specificity: Brain, heart, muscle most affected
- Energy crisis: Reduced ATP production in high-demand tissues
- Oxidative stress: Electron leak increases ROS production
Complex I dysfunction is a hallmark of PD:
- Complex I deficiency: Observed in PD substantia nigra
- Neurotoxin models: MPTP, rotenone target complex I
- NDUFS6 variants: Some variants associated with PD risk
- PINK1/Parkin pathway: Mitochondrial quality control linked to complex I
- Dopaminergic vulnerability: High energy demand makes neurons susceptible
Complex I involvement in AD:
- Reduced complex I activity in AD brain
- Amyloid-beta directly inhibits complex I
- Mitochondrial dysfunction precedes clinical symptoms
- NDUFS6 expression altered in AD
The mitochondrial electron transport chain (ETC) consists of four complexes:
| Complex |
Name |
Function |
Electrons From |
| I |
NADH:ubiquinone oxidoreductase |
NADH oxidation, proton pumping |
NADH |
| II |
Succinate:ubiquinone oxidoreductase |
Succinate oxidation |
FADH2 |
| III |
Cytochrome bc1 complex |
Electron transfer to cytochrome c |
Ubiquinol |
| IV |
Cytochrome c oxidase |
Electron transfer to oxygen |
Cytochrome c |
| V |
ATP synthase |
ATP synthesis |
Proton gradient |
Complex I contains:
- N module (NADH dehydrogenase): NADH binding and oxidation
- Q module (Quinone reduction): Ubiquinone reduction site
- P module (Proton pumping): Translocation of 4 H+ per NADH
NDUFS6 contributes to the Q module, which contains the ubiquinone binding site and several Fe-S clusters.
- Coenzyme Q10 supplementation: Electron carrier replacement
- L-carnitine: Improves mitochondrial metabolism
- Sodium bicarbonate: Manages lactic acidosis
- Dietary restrictions: Avoid fasting, high-fat diets
- Seizure control: Standard antiepileptic drugs
- Gene therapy: AAV delivery of functional NDUFS6
- Small molecules: Complex I assembly stabilizers
- mTOR inhibitors: Modulate metabolic stress
- Antioxidants: Mitigate oxidative stress
- Three-parent IVF: Germline mitochondrial replacement
- MRT for Leigh syndrome: Clinical trials ongoing
- Ethical considerations: Germline modification debates
NDUFS6 is ubiquitously expressed, with highest levels in:
- Brain: Cerebral cortex, cerebellum, spinal cord
- Heart: Left ventricle (high energy demand)
- Skeletal muscle: Type I fibers
- Liver: Hepatocytes
- Kidney: Tubular cells
- Mitochondrial matrix: Integral to complex I structure
- Inner mitochondrial membrane: Peripheral arm
- Neuronal soma: High density in perikarya
- Synaptic terminals: Mitochondria-rich
¶ Structure and Assembly
NDUFS6 is a small protein with:
- N-terminal region: Contains Fe-S binding motifs (Cys-XX-Cys-XX-Cys)
- C-terminal region: Interacts with other complex I subunits
- Co-factor binding: Requires Fe-S cluster assembly machinery
Proper complex I assembly requires:
- NDUFAF1-6: Assembly factors
- NFU1, BOLA3: Fe-S cluster assembly
- LYRM proteins: Lipoyl-binding assembly factors
- NDUFS6 mutations: Can affect assembly efficiency
- Genetic testing: Targeted NDUFS6 sequencing
- Biochemical testing: Complex I activity in musclefibroblasts
- Newborn screening: Some regions include mitochondrial disease panels
- Prenatal testing: For known familial mutations
- Leigh syndrome: Poor prognosis, early mortality
- Isolated deficiency: Variable, depends on residual activity
- Adult-onset: Generally more benign
Current research focuses on:
- Complex I structure determination
- NDUFS6 mutation spectrum and genotype-phenotype correlation
- Gene therapy approaches
- Mitochondrial replacement therapy
- Biomarker development for disease progression
In substantia nigra:
- High metabolic demand
- Complex I vulnerability in PD
- Dopaminergic neuron susceptibility
- Therapeutic implications
In hippocampus:
- Memory circuit functions
- Complex I in synaptic plasticity
- AD pathology involvement
- Energy metabolism
In cortex:
- Pyramidal neuron energy needs
- Complex I expression
- Cortical dysfunction in disease
In cerebellum:
- Motor coordination
- Purkinje cell energy demands
- Ataxia associations
¶ NDUFS6 and Protein Aggregation
In AD:
- Aβ inhibits complex I
- Mitochondrial dysfunction amplification
- Synaptic energy failure
- Therapeutic implications
In tauopathies:
- Mitochondrial dysfunction in tauopathy
- NDUFS6 in neuronal survival
- Energy crisis mechanisms
In PD:
- Complex I in dopaminergic neurons
- Alpha-synuclein effects on mitochondria
- Energy failure
- Energy requirements for activation
- Inflammatory responses
- Neuroprotection roles
- Metabolic support
- Mitochondrial function
- Astrocyte-neuron coupling
- Myelin energy demands
- White matter involvement
¶ NDUFS6 and Synaptic Function
- High energy demand
- ATP supply for neurotransmission
- Complex I role
- Energy failure
- Synaptic loss mechanisms
- Cognitive decline
- Ndufs6 knockout: Embryonic lethal
- Conditional knockouts: Tissue-specific
- Transgenics: Disease models
- Complex I deficiency
- Metabolic dysfunction
- Neurological phenotypes
¶ NDUFS6 and Cellular Stress
- ROS production
- Antioxidant systems
- Damage mechanisms
- Energy failure
- Glucose metabolism
- Therapeutic implications
- Mutation analysis
- Newborn screening
- Carrier detection
- Complex I activity
- Mitochondrial function
- Disease monitoring
| Approach |
Status |
Indication |
| Gene therapy |
Preclinical |
Mitochondrial disease |
| CoQ10 supplementation |
Clinical |
Complex I deficiency |
| Mitochondrial agents |
Various |
Neurodegeneration |
- Brain delivery
- Specificity
- Timing
- Efficacy
- Early intervention
- Combination approaches
- Personalized medicine
¶ NDUFS6 and Blood-Brain Barrier
- Mitochondrial agents
- Delivery challenges
- Dysfunction in neurodegeneration
- Therapeutic implications
¶ NDUFS6 and Aging
- Declining complex I activity
- Mitochondrial dysfunction
- Cognitive decline
- Antioxidants
- Exercise
- Mitochondrial support
- Metabolic dysfunction
- Neurodegeneration links
- Therapeutic implications
- Metabolic effects
- Brain energy metabolism
- CoQ10 in PD
- Mitochondrial agents
- Gene therapy approaches
- Variable efficacy
- Safety data
- Biomarker findings
- Blue-native PAGE
- Enzymatic assays
- Structure studies
- Patient fibroblasts
- iPSC-derived neurons
- Mitochondrial studies